Homozygosity mapping approach identifies a missense mutation in equine cyclophilin B (PPIB) associated with HERDA in the American Quarter Horse  by Tryon, Robert C. et al.
07) 93–102
www.elsevier.com/locate/ygenoGenomics 90 (20Homozygosity mapping approach identifies a missense mutation in equine
cyclophilin B (PPIB) associated with HERDA in the
American Quarter Horse
Robert C. Tryon a, Stephen D. White b, Danika L. Bannasch a,⁎
a Department of Population Health and Reproduction, School of Veterinary Medicine, University of California-Davis, One Shields Ave., Davis, CA 9516, USA
b Department of Medicine and Epidemiology, School of Veterinary Medicine, University of California-Davis, One Shields Ave., Davis, CA 9516, USA
Received 3 February 2007; accepted 19 March 2007
Available online 11 May 2007Abstract
Hereditary equine regional dermal asthenia (HERDA), a degenerative skin disease that affects the Quarter Horse breed, was localized to ECA1
by homozygosity mapping. Comparative genomics allowed the development of equine gene-specific markers which were used with a set of
affected horses to detect a homozygous, identical-by-descent block spanning ∼2.5 Mb, suggesting a recent origin for the HERDA mutation. We
report a mutation in cyclophilin B (PPIB) as a novel, causal candidate gene for HERDA. A c.115G>A missense mutation in PPIB alters a glycine
residue that has been conserved across vertebrates. The mutation was homozygous in 64 affected horses and segregates concordant with
inbreeding loops apparent in the genealogy of 11 affected horses. Screening of control Quarter Horses indicates a 3.5% carrier frequency. The
development of a test that can detect affected horses prior to development of clinical signs and carriers of HERDA will allow Quarter Horse
breeders to eliminate this debilitating disease.
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degenerative skin disease predominantly found in the American
Quarter Horse breed. The most common phenotypes are
seromas, hematomas, and ulcerations that develop primarily
along the dorsal aspect (Fig. 1A) and progressively worsen in
frequency and severity with age. Loose, sloughing skin (Fig.
1B) is characteristic of affected tissue and often represents an
early indication of the condition [1]. Severe lesions begin to
develop on average at 1.5 years of age (Fig. 1C) and can
deteriorate quickly (Fig. 1D) due to an inability to treat the
condition. Consequently, the majority of affected horses are
euthanized. Previous analyses have supported an autosomal
recessive mode of inheritance and a carrier frequency between
1.8 and 6.5% has been estimated [2].
Foals affected with HERDA rarely show symptoms at birth
and areas that develop lesions are focal and nonuniformly
distributed over the body. Many cases are not identified until the⁎ Corresponding author.
E-mail address: dlbannasch@ucdavis.edu (D.L. Bannasch).
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doi:10.1016/j.ygeno.2007.03.009horses have a saddle on their backs, and lesions are most
commonly found along the dorsal aspect, coincident with where
the saddle would rest. Accordingly, HERDA may be related to a
deficiency in wound healing or to dysregulation of inflamma-
tion. Histological examination does not definitively diagnose
the disease, although subtle signs of thinned and shortened
collagen fibers in the deep dermis and thinner skin thickness in
affected regions suggest a general disorganization in compar-
ison to control biopsies [1,3,4]. In two studies collagen 1 and
collagen 3 content were indistinguishable in affected and
unaffected horses [1,3].
Published case reports describing HERDA (also known as
hyperelastosis cutis) have compared the disease to Ehlers–
Danlos syndrome (EDS) [5]. Although the phenotype of loose
skin (Fig. 1B) in affected areas is consistent with EDS, the
normal quality of skin in unaffected areas of the body and the
disease's progressive nature suggest a distinct genetic cause.
Researchers have focused histologically on the disorganization
of collagen seen in affected tissue, yet unaffected tissue taken
from affected horses (either before they show signs of the
Fig. 1. Phenotype of HERDA-affected horses. (A) A 2-year-old HERDA-affected stallion with mild lesions concentrated along the dorsal aspect (white circle),
including early indications of loose, sloughing skin (white arrow). (B) Extensible skin in affected tissue can be more easily separated from the underlying fasciae. (C) A
large hematoma developed at approximately 1.5 years of age along the left dorsal side of this affected horse. (D) Additional ulcerations and degeneration of the skin as
seen on the right dorsal side of the horse shown in C.
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and consistent with control samples [6]. This indicates that the
natural growth and development of skin of an affected horse
may not be deficient with regard to de novo collagen
metabolism. Whether the protein product of the gene respon-
sible for HERDA directly interacts with collagen or more
broadly has an effect on posttrauma collagen deposition, part of
the wound-healing process, remains unclear.
The term quarter horse dates back to the 17th century and
derives its name from their use in short quarter-mile races in
colonial America. While there is no known definitive genetic
makeup of the original Quarter Horses, imports of English
racing stocks and horses that were introduced into North
America by early Spanish explorers factored heavily into the
breed in the 17th and 18th centuries. As settlers migrated
westward across North America, the Quarter Horse became
known for its versatility, strength, and agility, particularly as
these qualities relate to the horse's ability to work on ranches
and aid in managing cattle herds. An official registry of the
American Quarter Horse was begun in 1941 and as of today the
breed is the largest in the world, registering 165,057 new horses
in 2005 (AQHA Annual Report, 2005). While the majority of
horses are kept for recreational purposes, racing and otherperformance events which emphasize the Quarter Horse's
unique capabilities serve as additional factors that affect
breeding decisions within the population.
Here we report the first whole-genome scan used to identify
a novel disease gene in the horse. While genome scans have
been used to map the locus for cream dilution [7], gray coat
color [8,9], and appaloosa coat color [10] in horses, the
identification of equine disease genes has exploited human and
mouse disease models and relied on a candidate gene approach.
The unusual structure of horse families (half sibships) and their
relatively long generation times create a challenge for obtaining
multigeneration families that segregate a disease, particularly
one which does not develop on average until 1.5 years of age
[1]. Horses which become affected are often no longer owned
by the breeder and full siblings of an affected horse are often
never produced. The low incidence of HERDA resulted in our
dataset consisting primarily of affected horses and very few
samples from first-degree relatives when the study began. Since
a common ancestor could be identified on both sides of an
affected animal's pedigree [1], a homozygosity mapping
approach was taken to map the locus.
A scan of the genome identified regions identical-by-descent
in affected HERDA horses on the q arm of ECA1 (closest to
Fig. 2. Pedigree for mapping the HERDA locus and ECA1 LOD analysis. (A)
Pedigree of 11 affected horses (shaded black) that demonstrate the linebreeding
used in breeding programs. DNA from 41 unaffected relatives (shaded gray) and
all affected horses were used for LOD analysis. (B) Plot of LOD scores for nine
markers distributed across ECA1; the maximum score of 7.43 was associated
with microsatellite marker AHT58.
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polymorphisms (SNPs) developed from the ∼10-Mb interval
further refined the region to ∼2.5 Mb. Based on the genome
annotations of human, chimpanzee, mouse, dog, and cow, there
are roughly 20 genes in the candidate region. Sequence analysis
revealed a nonsynonymous mutation in exon 1 of equine PPIB.
This SNP segregates perfectly with HERDA and can be adopted
for identifying carriers and screening foals to determine future
disease status. The region of linkage disequilibrium within the
affected samples is large, therefore additional functional
analyses will be necessary to verify a causative link between
the PPIB mutation and HERDA.
Results and discussion
Mapping HERDA
Samples used in the genome scan consisted of 38 affected
HERDA horses and 44 unrelated control horses. Of 98
autosomal microsatellite loci tested, 13 exhibited significant
differences between expected heterozygosity values and an
unambiguous decrease of observed heterozygosity in the
HERDA horses compared to the general population (Table 1).
Potentially associated loci were further evaluated for significant
differences in allele frequencies using a χ2 test comparing the
two sampled populations. Only HMS15 and HMS7, two
markers that map ∼18 cM apart on ECA 1 [11], gave highly
significant p values (Table 1).
To confirm association to HERDA, 52 samples (Fig. 2A)
from 11 affected horses and 41 relatives were genotyped at nine
loci on ECA1. The average distance between markers was
16.8 cM [11] and the two markers (HMS15 and HMS7) which
were used to initially detect the reduction in heterozygosity
within the affected population were replaced by alternative
anchored markers for this stage of analysis. A maximum LOD
score of 7.43 was generated at marker AHT58 (Fig. 2B). With
the exception of flanking markers within 20 cM of AHT58, no
other marker on ECA1 generated a LOD score >0.0 (average
−0.7).Table 1
Identification of markers exhibiting increased homozygosity
Locus Chrom. Expected
heterozygosity
χ2 test of independence
Control HERDA χ2 d.f. p value
ASB41 1 0.733 0.580 6.40 6 0.380
HMS15 1 0.781 0.279 27.47 7 0.0003
HMS7 1 0.792 0.694 21.43 7 0.003
LEX34 5 0.723 0.664 3.24 5 0.663
AHT5 8 0.744 0.663 5.30 6 0.506
COR069 13 0.720 0.631 8.75 5 0.119
COR002 14 0.666 0.571 3.35 4 0.501
AHT2 15 0.751 0.614 6.28 4 0.179
B-8 15 0.736 0.623 7.95 8 0.439
LEX056 16 0.837 0.748 7.02 7 0.427
COR032 17 0.454 0.254 3.50 3 0.321
LEX36 19 0.725 0.632 4.40 9 0.883
A-17 26 0.834 0.777 4.75 8 0.785Fine-structure mapping
Initially, 10 microsatellites (Fig. 3B) that were previously
mapped by linkage or radiation hybrid analysis to a region near
the AHT58 marker [11,12] were used to further refine the
interval. Of 68 HERDA horses tested, 64 showed homozygosity
centered around the AHT58 marker (Fig. 3B). Eight samples
were homozygous at all 10 microsatellite markers, a region that
spans 32 cM [11], and presumably represent the ancestral
haplotype upon which the mutation arose. Fifty-six affected
samples contained a smaller block of homozygosity either
proximal and/or distal to but always containing the AHT58
microsatellite. Four samples diagnosed as affected in our dataset
clearly deviated from the HERDA haplotype.
Since the number of HERDA cases seen by veterinarians
began to increase in the late 1990s [1], multiple lay articles
informing Quarter Horse breeders of the disease have been
published. Lacking a definitive histological method for
diagnosing the disease, local veterinarians that suspected a
case of HERDA often submitted blood samples to UC Davis in
hopes of aiding the ongoing research into the genetic basis of
the disease. Although care was taken to effectively screen
submitted cases, issues of phenocopy and premature diagnosis
are suspected to have led to the incorrect inclusion of horses in
our affected dataset. The owners of these four genetically
dissimiliar (specifically in relation to markers on the q arm of
ECA1) cases were contacted to determine the current status of
each horse. Personal communication with one owner revealed
that no further lesions had developed and the horse had begun
training for performance events, consistent with a misdiagnosis.
A second horse was resampled and the atypical genotype across
Fig. 3. Comparative genomics and reduction of the critical interval containing the HERDA locus. (A) Genetic map of ECA1 [11] and position of nine markers used to broadly map the locus. (B) Blocks of homozygosity
found in HERDA-affected horses using microsatellite markers. Six of the microsatellites (1CA25 thru UCDEQ440) that comprise the HERDA ancestral haplotype (hash-marked bar) comprise a radiation hybrid group
[12] and indicate the relative order of these markers. Numbers below bars represent the number of affected samples sharing genomic blocks that are identical by descent. (C) Physical map of HSA15q used to develop
gene-based markers within equine homologues of human genes. The most significant (Supplemental Table 1) cross-species discontiguous MegaBLAST hit is shown for equine microsatellites to the left. Genes from
HSA15q in which informative SNPs were developed from equine homologues are shown to the right. (D) Fine-structure blocks of homozygosity found in HERDA-affected horses using novel SNP and microsatellite
markers. Numbers below bars represent the number of affected horses that share genomic blocks that are identical by descent.
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euthanized and no further analysis was possible. Horses are
subject to a number of dermatological conditions and novel
cases which mimic aspects of HERDA may have entered our
dataset. These cases highlight the importance of having an
accurate way to diagnose HERDA.
BLAST results (Supplemental Table 1) of 9 of the 10
microsatellites used to refine the area of homozygosity within
affected samples established a sequence-based framework for
comparing the equine and human genomes. Recent comparative
maps [11–13] demonstrate the region containing the HERDA
locus on ECA1q to be homologous to HSA15q. The highest
BLAST hits of the 9 microsatellites span HSA15, between 36 Mb
(UM026) and 75.49 Mb (1CA25). The relative order of markers
1CA25, UM043, HTG12, AHT58, UM004, and UCD440 as they
BLAST (Fig. 3C) to the human genome correlates with the order
of the markers as they appear on the first-generation whole-
genome radiation hybrid map (Fig. 3B) [12].
The general region of HSA15 was screened for genes
associated with EDS or related genes which were deemed
candidate genes based on similarities of phenotype. Human
lysyl oxidase like-1 (LOXL1) resides on HSA15q24 (71.94 Mb)
and is involved in the metabolism of collagen and elastin.
Sequencing of exon 1 from the equine LOXL1 in an affected
and unaffected Quarter Horse revealed a c.511C>G SNP that is
predicted to cause a p.171P>A missense mutation (Table 2). All
affected horses and a set of 16 unaffected horses were
genotyped at the SNP. Both alleles were found in the unaffected
control horses and affected horses. LOXL1 was excluded as the
determinant of HERDA.
Further investigation into other genes in the region did not
initially suggest a clear candidate gene. Additional gene-based
markers were discovered within the equine homologues of five
human genes (ITGA11, CILP, SPG21, USP3, and TLN2) that
map across the region of HSA15 (Fig. 3C). SNPs were found
within four of the five gene introns while a polymorphic
dinucleotide microsatellite was found within an intron of
SPG21 (Table 2). A subset of 14 affected samples which were
informative for defining the critical interval based on micro-
satellite genotypes and 10 unaffected, unrelated samples were
used for evaluating gene-specific markers. Three affectedTable 2
Informative genetic markers for refining the critical interval surrounding the HERD
Gene Primers Ta Size (bp)
TLN2 F: CTCGTCAGAAAATCAGTACTTCTC 61 948
R:CCAATCCCCACCCCAAGATA
USP3 F:AGCTTTCACAGCTGACAGGCATA 60 1640
R:TGAGTGACTGAAGGATGGCATTC
SPG21 F:VIC-TCATACTCTGACCCCGCTGATC 58 224–228
R: TTTAATTTTCCTTCCCACTCACG
CILP F:TGGTGCCTCAACAGGGAGCAG 62 1394
R:CACTTGCTCCAGGGAGACCA
ITGA11 F: ACCTGTCTTCCTGGCGCCC 59 1554
R: CAGCACATGGAAGTTGATCCGA
LOXL1 F: CGCACCTCGGTCTCCCAG 60 404
R: CTGTGCGAGTAGCGGCGGTsamples heterozygous for the intronic SNP in TLN2, proximal
to the HERDA locus, and 6 affected samples heterozygous for
the intronic dinucleotide repeat in SPG21, distal to the HERDA
locus, define the smallest identifiable critical interval to date
(Fig. 3D). Gene-specific markers for TLN2, SPG21, and
LOXL1 have been verified to cluster with markers previously
mapped to ECA1q21-23 by RH analysis (personal communica-
tion with T. Rausdepp, Texas A&M, Aug 31, 2006).
Mutation screen
The HERDA locus maps within a block of synteny that has
been conserved across human, chimpanzee, rhesus monkey,
dog, mouse, and rat. The region, which is typically bounded by
TLN2 and SPG21, is predicted to contain 20 known genes and 6
putative genes in humans (Supplemental Table 2). Additional
research into the functions of genes in the block led to the
sequencing of equine PPIB based on its peptidyl-prolyl cis-
trans isomerase function, a published association with procolla-
gen [14–16], and the role of extracellular cyclophilins in the
inflammatory response [17].
Two SNPs predicted to cause missense mutations were found
in PPIB by sequencing cDNA (GenBank Accession No.
EF397503) from skin of an affected and an unaffected horse.
All four introns of PPIB were sequenced and no SNPs were
found. PPIB*1 (c.17A>G), predicted to cause a glutamic acid to
glycine change (p.6E>G) in the putative endoplasmic reticulum
(ER) signal sequence, was homozygous (PPIB*1/PPIB*1, 3 of
16) and heterozygous (PPIB*1/+, 6 of 16) in unaffected horses,
indicating that it is not causative for HERDA. PPIB*HRD
(c.115G>A) (Fig. 4A inset), predicted to cause a glycine to
arginine change (p.39G>R) in the putative N-terminal domain
of the protein following ER signal cleavage, was not found in
any of the 16 unaffected horses tested. Seven affected horses
were homozygous (PPIB*HRD/PPIB*HRD), eight unaffected
relatives were heterozygous (PPIB*HRD/+), and a single
unaffected full-sibling was homozygous for the wild-type
SNP (+/+).
An assay was developed (Fig. 4A) so that large numbers of
samples could be screened for the presence of PPIB*HRD. All
64 HERDA samples that contained a block of homozygosityA locus
Sequencing
primer
Bases
from end
SNP w/ flanking sequence
R 155 Control: GGAGAACCCACAAGC
HERDA: GGAGAACTCACAAGC
F 340 Control: AACACCCACTCATGT
HERDA: AACACCCGCTCATGT
N/A N/A Control: 224, 226, 228
HERDA: 226
R 154 Control: AGACAGGGTTTATGT
HERDA: AGACAGGATTTATGT
R 79 Control: CGGTCCCCGCCCTCA
HERDA: CGGTCCCAGCCCTCA
F 85 Control: CCAGCCGCCCTCCTT
HERDA: CCAGCCGGCCTCCTT
Fig. 4. c.115G>A substitution in exon 1 of equine PPIB. (A) Genotyping assay of normal, heterozygote, and HERDA-affected horses with corresponding direct
sequence reads (inset). Predicted amino acids are shown above the nucleotide sequence. (B) Protein sequence alignment (Vector NTI) of the first 100 residues of PPIB
from an affected horse, a normal horse, five mammals, and three nonmammalian vertebrates. The two mutations detected in affected horses are indicated with an
asterisk. As p.6E>G is commonly found in the Quarter Horse breed, p.39G>R is the putative causal mutation responsible for HERDA.
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PPIB*HRD) for the mutation (Table 3). None of the 4
genetically distinct horses that had previously been flagged as
potential misdiagnosed cases carried the HERDA allele (+/+, 4
of 4). Thirty-four available parents of affected horses were
heterozygous (PPIB*HRD/+), consistent with the autosomal
recessive nature of the disease. A χ2 test of 13 genotyped triosindicates that the expected number of affected horses with a
PPIB*HRD/PPIB*HRD genotype (3.25) is significantly differ-
ent (p<0.001) from that observed (13). Using binomial
probability, the likelihood of all 13 affected horses being
homozygous for PPIB*HRD is p=1.5×10−8.
Previous pedigree analysis of the families used in establish-
ing a LOD score for the HERDA locus display an inbreeding
Table 3
PPIB c.115G>A SNP genotypes
Sample set +/+ PPIB*HRD/+ PPIB*HRD/
PPIB*HRD
Total
Affected HERDA 4 a 0 64 68
Unaffected relatives 18 58 0 76
→Obligate carriers 0 (34) 0
Unaffected control 1041 38 0 1079
Other breeds 55 0 0 55
Total 1118 96 64 1278
a Horses were genotypically inconsistent with all other (64) HERDA-affected
samples in relation to microsatellite and SNP markers along ECA1q. These
cases likely represent misdiagnosis or phenocopy due to an inability to diagnose
the disease histologically.
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the mutation. In all cases, PPIB*HRD segregates in a
predictable fashion consistent with the hypothesis that inbreed-
ing is leading to the union of two mutant alleles which are
identical-by-descent. A set of 1079 unaffected Quarter Horses
collected from the UC Davis Veterinary Medical Teaching
Hospital and the UC Davis Veterinary Genetics Laboratory
(VGL) were screened for the mutation (Table 3). Thirty-eight
samples were heterozygous for the mutation, suggesting a 3.5%
carrier frequency, which agrees with previous estimates of 1.8 to
6.5% [2]. No control Quarter Horses were detected to be
homozygous for the mutation from this sample set. A small
sampling of Arabians (18), Paint Horses (28), and draft horses
(9) were tested and only the wild type allele was detected.
The HERDA-predicted PPIB protein and one of the two
equine wild-type variants were aligned with five mammalian
and three nonmammalian vertebrate (Danio rerio, Xenopus
tropicalis, and Gallus gallus) PPIB sequences (Fig. 4B). Equine
PPIB shared the highest identity (97.7%) with canine PPIB. The
six mammalian PPIB sequences were 88% identical. Across
sequenced vertebrates, the glycine residue that is mutated in
HERDA horses is invariant. The glycine sits in the third
position of a completely conserved seven-amino-acid peptide
(37KKGPKVT43) structure that has been strictly maintained
throughout vertebrate evolution.
PPIB as a compelling candidate causal mutation for HERDA
in the American Quarter Horse
The detection of unique polymorphisms in the identical-by-
descent critical interval was a first step toward developing a
definitive genetic test for HERDA. Of the 64 affected horses
which share the characteristic HERDA haplotype across ECA1,
four DNA markers have been determined to be homozygous in
all samples: the A→G intronic SNP of USP3 (Table 2), the
c.17A>G exonic SNP (PPIB*1) predicted to cause a missense
mutation of PPIB, the c.115G>A exonic SNP (PPIB*HRD)
predicted to cause a missense mutation of PPIB, and the 185
allele of the AHT58 microsatellite marker. Of these four
markers, the c.115G>A missense mutation in PPIB is the only
polymorphism unique to families segregating for HERDA
and only affected horses were homozygous. Equine cDNAsequence from an additional 12 genes (GenBank Accession
Nos. EF397504–EF397516) predicted in the block of identity-
by-descent have been interrogated and no SNPs have been
found in coding sequence.
PPIB is a member of the peptidyl-prolyl isomerase (PPI)
gene family. Human and mouse genomes each have eight PPI
family members (PPIA–PPIH), which contain a conserved
active domain and alternative N- and C-terminal domains
specifying the individual PPI family member. This family of
genes, of which PPIA is the most comprehensively studied, is
implicated in protein folding, immune response via its binding
of cyclosporine A, and T cell activation. Although naturally
occurring PPI mutants have not been reported, a mouse PPIA
knockout was shown to be viable and 30% of ppia -/- mice
developed a progressive form of blepharitis, or inflammation of
the eyelids, beginning at 3 months of age and elevated Th2
cytokine production [18]. The fact that PPI deficiencies are
tolerated biologically and produce an adult-onset inflammatory
phenotype supports PPIB as a causal candidate mutation for
HERDA.
PPIs have been implicated in protein folding of collagens via
their cis-trans peptidyl-prolyl isomerase function [14–16].
Structural collagens contain a high percentage of proline
residues (average 18% in humans) which are necessary for
the proper formation of collagen fibrils. Kinetic studies of
collagen folding indicate two steps in fibril formation, the
slower of which is limited by the cis-trans isomerization of
proline residues in the collagen chain [19]. Histological
examination of affected tissue has consistently shown dis-
organization of collagen. While it remains unclear whether
deficient collagen folding is related to the development of
severe seromas and ulcerations, PPIB is a logical candidate
gene that would explain a portion of the histological phenotype
observed in affected HERDA tissue.
Work on PPIB has clearly demonstrated two important
binding sites: type I corresponding to functional receptors and
type II corresponding to sulfated glycosaminoglycans [20].
Site-directed mutagenesis experiments demonstrated that T-
lymphocyte adhesion to the extracellular matrix, specifically
fibronectin, is dependent on the ability of PPIB to bind
glycosaminoglycan [21,22]. Three lysine residues in the N-
terminal domain of PPIB are essential for heparin sulfate
binding and consequently appropriate T-lymphocyte adhesion.
The mutated p.39G>R seen in HERDA horses is immediately
downstream of the lysine triplet 36KKK38 (Fig. 4B). Based on
this cumulative empirical evidence, one hypothesis is that
mutation of the compact glycine residue into a large, charged
arginine introduces steric hinderance, resulting in altered
heparin sulfate binding. Complicating our elucidation of the
effects of this p.39G>R mutation on PPIB function is the fact
that arginine, which is similar in size and charge to lysine, has
been shown to have a higher affinity for heparin than lysine
[23]. Due to the multiple functions associated with PPIB and the
poorly characterized pathways that lie downstream of the
protein with regard to intercellular signaling [24], it is difficult
to predict how a mutation in this gene would manifest itself
biologically.
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The increase inHERDAcases during the late 1990s is intriguing
from a population genetics perspective. Similar to many other
domesticated animal species, Quarter Horse breeders commonly
use linebreeding to select for desirable qualities. While the breed
can be used for a wide variety of recreational activities, pedigree
analysis of HERDA horses suggests that the disease is concen-
trated within particular lines of cutting horses. Cutting is a term
used to describe the process of singling out and isolating an
individual from a herd of cattle and maintaining that separation, as
would be practical on a ranch. Horses require training to hone their
skills and speed, agility, and “cow sense” are paramount to
mastering the art of cutting. Competitions were begun in 1898 and
have grown considerably during the past century, with National
Cutting Horse Association approved events offering total purses
exceeding $39million as of 2006. Success at cutting events and the
money which accompanies that success has consequently had a
profound impact on the selection of breeding stallions.
A number of obligate carriers have contributed disproportio-
nately to the breeding population of Quarter Horses within the past
2 decades. Inbreeding loops evident in many of the affected horses'
pedigrees trace back to these popular sires and invite the
hypothesis that a heterozygous genotype may confer an advantage
as it relates to cutting. Whether PPIB*HRD or the larger haplotype
associated with the allele has been under selection remains unclear.
Further functional work would be required to establish such a
heterozygous advantage. Regardless, robust breeding of carrier
stallions has likely led to an increase in the allele frequency and the
use of linebreeding has resulted in a higher incidence of affected
HERDA cases. The PPIB*HRD allele which has been found in
perfect association with the HERDA phenotype will be useful to
Quarter Horse breeders for two reasons. First, in cases where a
young horse begins to show skin irregularities, the test will give
owners the chance to genetically determine whether HERDA is the
cause and prevent a potentially unnecessary euthanasia. Second, it
will allow breeders the opportunity to identify carriers within the
breeding population and minimize the production of affected
HERDA horses.
Materials and methods
DNA and tissue samples
Diagnosed cases of HERDA and control samples were collected as
previously reported [2]. With the permission of the American Quarter Horse
Association (AQHA), backlogged hair root samples of relatives of affected
horses were made available from the VGL, which conducts parentage testing for
all registered American Quarter Horses. Genomic DNAwas isolated from blood
samples using the Qiagen Blood Mini-Kit (Qiagen, Valencia, CA). Genomic
DNA was isolated from hair root samples by the VGL [8]. The sample set
consisted of 68 horses diagnosed with HERDA, 76 unaffected relatives, 1079
Quarter Horses to serve as controls, and 55 horses of diverse heritage (Arabians,
Paint Horses, and draft horses).
Microsatellite genotyping
Most fluorescently labeled primer sets were obtained with the help of the
Dorothy Havemeyer Foundation. Primers for additional published microsatellitemarkers were obtained from Applied Biosytems (Foster City, CA). Multiplex
reactions for the initial genome scan were based on previous reports [8] and
personal communications with the VGL. Data for 27 of the 100 loci screened in
the genome scan were generated by the VGL as part of their standard parentage
panel and genotyped in three multiplex reactions. Sixty-seven additional
markers were combined into 14 multiplex reactions. Seven microsatellites were
individually amplified. Amplifications were performed in 25 μL total volume
containing 1 μL genomic DNA (∼20 ng), 1× PCR buffer, 2.5 mM MgCl2,
250 μM dNTPs, 1 unit AmpliTaq Gold (Applied Biosystems) with primer
concentrations and annealing temperatures specified in Supplemental Table 3.
For fine-structure mapping, markers spanning ECA1 were amplified in 20 μL
total volume containing 1 μL genomic DNA, 1× PCR Buffer, 1.5 mM MgCl2,
125 μM dNTPs, 0.5 units AmpliTaq Gold with primer concentrations and
annealing temperatures specified in Supplemental Table 4. All microsatellite
data was analyzed with an ABI 3100 Genetic Analyzer (Applied Biosystems)
and STRAND software (http://www.vgl.ucdavis.edu/STRand/).
Statistics
Allele and genotype frequencies were counted within the control population
(n=44) and the affected population (n=38) at 98 autosomal microsatellite loci. For
each group, the expected heterozygosity values with standard errors and observed
heterozygosity values of each locus were computed with Arlequin software [25]. A
χ2 test assigned p values by testing the null hypothesis that the two population
samples have the same allele frequencies. An L×2 contingency table with L-1
degrees of freedom, where L=No. of alleles present at a given locus, were used.
LOD scores were generated using HOMOZ/MAPMAKER software [26].
Establishing a comparative framework
Published microsatellite sequence from ECA1q was compared to the Equus
caballus whole-genome sequence (WGS) Trace Archives using Discontinuous
MegaBLAST (http://www.ncbi.nlm.nih.gov/blast/tracemb.shtml). Five hundred
bases were mined 5′ and 3′ to the polymorphic dinucleotide repeat to generate
>1000 continuous bases of equine sequence. Those sequences which contained
informative equine genetic markers were compared to the human genome
sequence (Build 36.2) using BLAST (http://www.ncbi.nih.gov). A significant
similarity match between equine and human sequences was set at an alignment
score (S)>60 and a sum probability value (E)<3.0 E-06, similar to a previous
report [27]. Subsequently, the region of the human genome identified with
BLAST comparisons was compared with other fully and partially mapped
mammalian genomes using the UCSC Genome Browser to confirm conserva-
tion of synteny across species (http://genome.ucsc.edu). A list of equine
candidate genes was generated from the region of synteny from the human
genome (Build 35.1). The Horse Genome Project (http://www.tiho-hannover.de/
einricht/zucht/hgp/index.htm) was searched for equine BAC clones which had
both ends successfully sequenced and that BLASTwithin 250 kB of each other
on HSA15, surrounding the region of identity by descent [28]. These BAC
clones provided additional confidence in the physical relationship between
ECA1 and HSA15 and helped to verify our candidate gene list. Equine gene-
specific markers were optimized with the 5000 rad equine radiation hybrid (RH)
panel and submitted for analysis [12].
SNP discovery and genotyping
Genes for SNP discovery were selected based on their spacing and the
availability of mammalian mRNA sequences from the GenBank database.
Sequences from all available mammals (typically human, mouse, dog, and cow)
were aligned (Vector NTI) and searched for regions of high conservation across
species. In addition, human and mouse mRNA sequences were analyzed using
the BLAT function of the UCSC genome browser (http://genome.ucsc.edu) to
determine intron/exon boundaries and the trend in intron size. Introns which had
conserved sizes between 700 bp and 3 Kb were targeted to facilitate cloning and
sequencing. These features were used to design primers for amplification of
specific homologous sequences from the horse genome.
Genomic DNA from an unaffected and an affected Quarter Horse were used
to amplify corresponding genomic fragments for each of the genes in Table 2.
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CA), sequenced, and verified by BLAST analysis to ensure that both ends of
cloned exonic sequence were indicative of the targeted gene. Clones were
aligned to identify gene-specific intronic SNPs or microsatellites. To genotype
SNPs from additional affected horses and unaffected controls, genomic
fragments were amplified, purified with the Qiaquick Purification Kit (Qiagen,
Valencia, CA), and sequenced on an ABI 3100 Genetic Analyzer with one of the
gene-specific primers used in the original amplification. The polymorphic
microsatellite within the intron of SPG21 was genotyped using a fluorescently
labeled primer as previously described.
Sequencing of candidate genes
Skin fibroblasts derived from dermal punch biopsies (Animal care protocol
No. 10714) taken from an affected HERDA horse and an age-matched
unaffected Quarter Horse were used to generate cDNA libraries (Fast Track 2.0
mRNA Isolation Kit, Invitrogen; Marathon cDNA Amplification Kit, BD
Biosciences). 5′ and 3′ RACE reactions were carried out with appropriate
reverse and forward primers (Supplemental Table 5), separated by gel
electrophoresis, extracted, and sequenced directly to obtain coding and partial
5′UTR and 3′UTR. For PPIB, additional primers were designed to generate
sequence of the four predicted introns (Supplemental Table 5). When equine
whole-genome sequence trace archives became available (spring 2006), equine
homologues of human genes from the syntenic region were computationally
mined. Discontinuous MegaBLAST was used to design primers that generated
maximal equine coding sequence. cDNA products were amplified, cloned, and
sequenced to identify additional SNPs between the affected and the unaffected
cDNA libraries.
DNA testing
Primers were designed to amplify a fragment of the PPIB gene, which
contains an informative SNP, from equine gDNA. An unlabeled forward primer
(5′CGGTGGATGCTGCGTTTCT) and a fluorescently labeled reverse primer
(5′6FAM-GCCCAAGCCAGCCTAGGA) generate a 250-bp fragment that is
susceptible to EarI restriction endonuclease digestion following amplification.
An EarI site cuts 46 bp from the end of the forward primer and serves as an
internal control to verify that the enzyme is working properly. The informative
SNP detected in the HERDA population introduces a second EarI site that cuts
67 bp from the first EarI site.
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